Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism.
about
Gene therapy for ischemic heart diseasecGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytesAdiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanismsHypoxia-induced left ventricular dysfunction in myoglobin-deficient mice.Protective vascular and cardiac effects of inducible nitric oxide synthase in mice with hyperhomocysteinemia.Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase- and soluble guanylate cyclase-dependent mechanisms.The late phase of preconditioning and its natural clinical application--gene therapyAldose reductase decreases endoplasmic reticulum stress in ischemic hearts.Preconditioning: a paradigm shift in the biology of myocardial ischemiaThe COX-2/PGI2 receptor axis plays an obligatory role in mediating the cardioprotection conferred by the late phase of ischemic preconditioning.Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models.Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequencesCardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway.The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats.Inducible nitric oxide synthase promoter polymorphism affords protection against cognitive dysfunction after carotid endarterectomyGene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions.Myocardial protection by nitriteDesigning heart performance by gene transfer.Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway.Nitric oxide mechanisms of nebivolol.Exercise does not increase cyclooxygenase-2 myocardial levels in young or senescent hearts.Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury.Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences.Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.Cross talk of the first-line defense TLRs with PI3K/Akt pathway, in preconditioning therapeutic approach.Tadalafil prevents acute heart failure with reduced ejection fraction in mice.Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure.MyD88 and NOS2 are essential for toll-like receptor 4-mediated survival effect in cardiomyocytes.Metallothionein Preserves Akt2 Activity and Cardiac Function via Inhibiting TRB3 in Diabetic Hearts.
P2860
Q24632135-91643DA4-723E-42D4-AFAC-B5F41C3C4874Q28577644-8F4CEB02-2995-46C1-B6EB-73E3E28F4674Q33688706-4FFAED43-6730-466C-8C75-67185C48342AQ33967356-68D26895-6520-4819-97ED-AEAE283FB829Q34203276-41A3E1F3-6A9B-40B0-A3EA-3B2295529369Q34605156-39AFFCA2-874F-4884-9434-46319F7F19E9Q34633367-D844C1A0-5515-4A7C-A1FC-E74DC437E8C5Q35227388-0CD10599-A0B0-4ED2-805D-E894A919BB5EQ35622752-FB15DA39-B075-4B9A-9E4D-C87FDFE31832Q36109838-B30C5D08-DF25-4679-9D69-1047EA0ABA1EQ36806912-DD9363E9-667E-4EEF-AAAB-4017A80F0452Q36829373-09042066-0C38-4897-A9EF-A1F115E701A5Q36845202-792D4D2C-D830-477C-B463-F87F6EE4314BQ37019371-C40170B4-B583-4D55-A987-BE1838A0026AQ37172702-3EA64001-E9E8-4A9F-B99D-824C47C56A35Q37222788-74758E88-8874-4171-8391-DA6B64E0E734Q37240946-E461F340-338F-467B-BF8A-3F13CCC9B084Q37299072-1C84AE92-D2D2-480B-83F2-7BCAE1125B50Q37401916-7E51FBF7-986C-4E76-A753-C4A9CA6341A7Q37483065-30F2B0FA-A8FD-4708-A8B1-311532A6D79DQ40012886-45475AD8-3F4A-4067-8381-D7373A6DE981Q40257008-5B2EA33C-DBB1-4F8A-8CB0-B56CE1843A46Q40257549-6E563AA1-90D7-4AB5-8375-D8FC8820E3BBQ40258000-56C6CD98-73F3-44F7-A53F-90C3B3EEB59AQ42157765-2C15532D-8C0E-4D5F-A0A0-B1AFB531AC20Q45004611-9C3355D6-0EBE-4BD9-928C-2160D6FBD283Q48194167-8DE12534-C1AF-40B1-9F68-1A4FB903B52FQ48703841-07B03B69-C70C-4091-BB83-941B3BEB7B50Q50100433-FC987494-7576-4EEA-B104-BE9026759A74
P2860
Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Gene therapy with inducible ni ...... ygenase-2-dependent mechanism.
@en
type
label
Gene therapy with inducible ni ...... ygenase-2-dependent mechanism.
@en
prefLabel
Gene therapy with inducible ni ...... ygenase-2-dependent mechanism.
@en
P2093
P2860
P1433
P1476
Gene therapy with inducible ni ...... ygenase-2-dependent mechanism.
@en
P2093
Charles J Lowenstein
Qianhong Li
Roberto Bolli
Sumanth D Prabhu
Susan C Stevenson
Wen-Jian Wu
Yanqing Zhu
Yu-Ting Xuan
P2860
P304
P356
10.1161/01.RES.0000065441.72685.29
P577
2003-04-01T00:00:00Z